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Abstract
Over 100 FDA-approved medications include pharmacogenetic biomarkers in the drug label,
many with cancer indications referencing germline DNA variations. With the advent of next-
generation sequencing (NGS) and its rapidly increasing uptake into cancer research and clinical
practice, an enormous amount of data to inform documented gene-drug associations will be
collected, which must be exploited to optimize patient benefit. This state-of-the-art article focuses
on the implementation of germline cancer pharmacogenetics into clinical practice. Specifically, it
discusses the importance of germline variation in cancer and the role of NGS in pharmacogenetic
discovery and implementation. In the context of a scenario where massive NGS-based genetic
information will be increasingly available to health stakeholders, this review explores the ongoing
debate over the threshold of evidence necessary for implementation, provides an overview of
recommendations in cancer by professional organizations and regulatory bodies, discusses
limitations of current guidelines and strategies to improve third-party coverage.
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Introduction
There is diffuse heterogeneity in response to cancer therapy, with only about 25% of patients
responding to conventional methods of choosing chemotherapy regimens (1). Additionally,
dose-limiting toxicities combined with poor target selectivity commonly result in delay or
cessation of therapy owing to reduced drug efficacy in the potentially curative setting.
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Understanding and applying the knowledge of a patient's cancer genome to resolve these
clinical problems has become increasingly utilized. In fact, prospective testing for somatic,
or acquired, mutations within a tumor and appropriate selection of targeted therapies is
beginning to replace standard of care administration of non-specific cytotoxic agents in
many tumor types, owing to enhanced survival and reduced toxicities. For example, the v-
Raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor, vemurafenib, has
replaced the standard of care, dacarbazine, for the treatment of metastatic melanoma patients
harboring the BRAF V600E mutation (2). The same has been seen with crizotinib as a
replacement for cytotoxic chemotherapy as standard first-line therapy in anaplastic
lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC) (3), trastuzumab in
human epidermal growth factor receptor-2 (HER2) positive breast cancer (4), erlotinib and
afatinib for epidermal growth factor receptor (EGFR) positive NSCLC (5, 6), and several
others.
While somatic mutations in genes coding for targets of mechanisms of action of drugs are
commonly used to predict pharmacodynamics and drug response, germline, or inherited,
genome variation can be helpful in predicting pharmacokinetics and/or pharmacodynamics
in individual patients (7) (Figure 1). Prospective identification of germline variants may aid
in normalization of systemic drug exposure and minimization of drug toxicity while
preserving the antitumor activity at the target site, thus enhancing clinical benefit. For
example, patients carrying the uridine-diphosphate glucuronosyl transferase 1A1*28
(UGT1A1*28) allele have decreased enzymatic activity, resulting in reduced glucuronidation
and impaired inactivation of 7-ethyl-10-hydroxycamptothecin (SN-38, the active component
of irinotecan) (8). These patients are recommended to receive a reduced initial dose of
irinotecan to minimize drug exposure and reduce severe, dose-limiting toxicities, such as
grade 3/4 neutropenia (9). Likewise, patients receiving 6-mercaptopurine and harboring low
activity thiopurine-S-methyltransferase (TPMT) phenotypes have increased production of
the active thioguanine nucleotide metabolites, which subsequently increases the risk of
myelosuppression and gastrointestinal toxicity (10-12). Six-mercaptopurine dose reduction
in TPMT-deficient patients has been shown to reduce the risk of toxicity associated with
high concentrations of thioguanine nucleotides without compromising efficacy (12, 13).
In addition to predicting the pharmacokinetics of a drug, germline variants may also inform
cancer biology (14). It is well established that immune cells can be tumor promoting through
their ability to regulate angiogenesis, cell proliferation, and tumor invasiveness (14).
Furthermore, neovascularization (angiogenesis) promotes tumor growth through the
formation of vasculature required to provide nutrients and oxygen to cancer cells while
removing wastes (e.g., carbon dioxide). In addition to the immune system and angiogenesis,
other systems that do not have the typical somatic alterations of a tumor include
inflammation and the stromal microenvironment. Germline variation in genes regulating
these systems may affect tumor growth and survival. Initial genome-wide association studies
(GWAS) of outcome of cancer patients treated with chemotherapy are corroborating the
hypothesis of germline determinants of cancer outcome being related to these systems. For
example, a germline GWAS of treatment response in childhood acute lymphoblastic
leukemia (ALL) selected the interleukin 15 gene (IL15) a determinant of minimal residual
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disease, a predictor of outcome (15). Another GWAS of overall survival (OS) in pancreatic
cancer patients treated with first-line gemcitabine revealed another gene in the immune
system (the interleukin 17F, IL17F) as associated with OS (16). These studies are supportive
of the notion that utilizing germline variation might predict not only drug behavior but also
host and tumor biology, subsequently enhancing our understanding of the genetic basis of
drug response in cancer.
An extensive number of reviews of the role of germline pharmacogenetics in cancer therapy
are readily available in the literature (17-20). In addition, an appreciation of the clinical
relevance of both germline and somatic pharmacogenetics can be gained from the number of
validated, clinically significant biomarkers listed in Table 1. Despite the vast number of
pharmacogenetic associations important in cancer treatment, very few pharmacogenetic tests
are utilized routinely in clinical practice. This state of the art article will focus on the
implementation of germline cancer pharmacogenetics into clinical practice. Specifically, we
will elaborate on the importance of NGS in germline cancer pharmacogenetics
implementation. We will explore the debate centered around the level of evidence required
to warrant clinical implementation, provide an overview of the landscape of
recommendations on pharmacogenetics implementation by professional organizations and
regulatory bodies, and discuss the limitations of the current guidelines. Finally, because the
uptake of pharmacogenetics into routine clinical practice is strongly influenced by third-
party coverage, we will discuss limitations and strategies to improve the current
reimbursement rates and, subsequently, translation of cancer pharmacogenetics into practice.
Maximizing benefit from next-generation sequencing efforts
The advent of NGS has allowed sequencing of an entire human genome at a reasonable cost
– the cost of sequencing one genome in 2001 was approximately $100 million, and in 2013
is less than $3000 (21). Additionally, the time required to sequence an entire human genome
has also decreased dramatically; from over a decade (1990 – 2003) to complete the
sequencing of the first human genome (the Human Genome Project), compared to as quickly
as a one-day turnaround time offered with some 2013 technologies (e.g., Benchtop Ion
Proton™ Sequencer, Life Technologies, Grand Island, NY) (22). This rapid decline in price
and turnaround time has resulted in an increase in research and clinical applications of
sequencing, most notably in cancer. Major academic institutions and both government-
sponsored and private organizations have launched programs for NGS of the cancer genome,
with the goals of describing the architecture of cancer-specific somatic alterations and of
aiding clinicians in selection of targeted therapy (23).
Because tumor samples contain both acquired and inherited alterations, along with somatic
DNA, cancer sequencing efforts also capture germline information. More importantly, in
cancer patients, germline DNA is oftentimes also analyzed as a means to identify variants
in the tumor. As discussed, this germline information plays a crucial role in optimizing the
dose and selection of therapy. An additional benefit unique to NGS is the ability to discover
rare variants in the genome and their impact on drug response. In a study exploring the
impact of rare variants versus common variants in SLCO1B1 on methotrexate clearance,
Ramsey and colleagues found that rare damaging nonsynonymous SNPs accounted for
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17.8% of the gene's effects on methotrexate clearance (24). Additionally, the rare variants
had larger effect sizes than the common nonsynonymous variants, with effect size being
inversely proportional to minor allele frequency. Whereas this group had to perform deep
resequencing of SLCO1B1 to discover these rare variants, the advent of NGS provides the
opportunity to obtain comprehensive (genome-wide) catalogues of rare variants.
Additionally, the larger effect sizes observed with rare variants likely contribute to the
overall phenotypic variability of drug response in cancer patients treated with chemotherapy.
In addition to pharmacogenetic research and discovery, germline information generated
through NGS has clinical applications, as it informs on drug selection and dose optimization,
as well as genetic susceptibility to disease, with cascade testing for the relatives of the
patient (Figure 2). In their 2010 recommendations for genetic testing for cancer
susceptibility, the American Society of Clinical Oncology (ASCO) reported nine genes with
well-validated germline variants predictive of cancer susceptibility (25). For example,
germline variants in the adenomatous polyposis coli (APC) gene result in a hereditary
condition known as familial adenomatous polyposis. Without any intervention, 100% of
these patients will ultimately progress to colorectal cancer (26). Similar risks are conferred
with the early onset breast cancer gene (BRCA) variants and breast and ovarian cancers
(27), as well as the DNA mismatch repair gene variants, which result in Lynch syndrome
and, subsequently, colorectal cancer (26).
As of August 2013, there are over 100 drugs with pharmacogenetic information in the U.S.
Food and Drug Administration (FDA)-approved drug labels, with 31 being cancer drugs,
and 8 of the cancer drugs referencing germline variants (28). NGS is able to provide data to
inform most or all of these validated gene-drug associations (i.e., some sequence
information may be missed in the case of whole exome sequencing) as well as many others
that are under investigation but have yet to confer a label change. Therefore, NGS of the
cancer genome is likely the most effective strategy for obtaining preemptive germline
assessment of actionable genotypes in cancer patients. It is important to exploit this germline
information, determine which variants are validated, warranting clinical implementation,
and optimize patient therapy accordingly.
With the many centers and companies now performing NGS and recommending therapy
changes based on the results, collaboration to accumulate data would also help maximize the
benefit of these efforts. Rather than waiting on data from prospective studies, the large
sample sizes would provide the means to retrospectively analyze large patient cohorts for
discovery of common and rare variants, validation, and outcomes of pharmacogenetic–based
decision-making. One collaborative organization working toward maximizing benefit from
NGS projects in all therapeutic areas is the Electronic Medical Records and Genomics
(eMERGE) Network, which is a national consortium focused on combining DNA
biorepositories with electronic medical records to facilitate large-scale, high-throughput
genetic research and returning genetic testing results to patients in a clinical setting (29).
Efforts such as this should be exploited from all angles, including somatic and germline
variation discovery and implementation, as well as clinical and uptake outcomes. On an
even broader scale, collaboration of international pharmacogenetics consortiums would
provide the basis for understanding population-based genetics and the impact of race on
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outcomes worldwide (30). This information may be beneficial in advancing clinical uptake
of pharmacogenetics throughout a wide spectrum of health care systems, including those in
third-world countries.
Level of evidence to warrant implementation
Generation of clinical recommendations and guidelines is burdened by the debate
surrounding the threshold of evidence required for translation of pharmacogenetics into
clinical practice. The U.S. Office of Public Health Genomics’ Evaluation of Genomic
Applications in Practice and Prevention (EGAPP) Working Group has identified the most
significant challenges in developing evidence-based reviews and recommendations for
genetics testing, which include: (1) uncertainty and difficulty in establishing clinical validity
(i.e., how consistently and accurately the test predicts the outcome of interest), (2) lack of
direct evidence of clinical utility (i.e., how likely the test is to significantly improve patient
outcomes), (3) rapid development and marketing of tests, and (4) lack of robust regulatory
infrastructure for genetic testing (31). These limitations contribute to the vast disparities
between recommendations, and therefore must be addressed.
While prospective randomized clinical trials (RCTs) are the gold standard and often required
for an intervention to be accepted into standard of care, this may not be the ideal study
design to demonstrate clinical utility of pharmacogenetics. The feasibility of performing
prospective, phase III, RCTs for each pharmacogenetic association discovered is unlikely
due to the inherent costs, time, and large sample sizes associated with these trials, which
may ultimately deprive many patients of safer and more effective treatments and dosing. To
increase efficiency, the focus may be shifted toward retrospective validation and replication
(32), randomized phase II studies (33), or adaptive trial designs that allow prospectively
planned modifications in design after patient enrollment(34). Unfortunately, alternative
approaches such as these may not completely eliminate the need for solid evidence from
traditional RCTs, which we have been accustomed to for over 60 years; however, it must
also be considered that many laboratory biomarkers in clinical use today have not been
tested for their predictive power in randomized studies. The level of evidence considered
appropriate to warrant recommendations according to the National Institute of Health's
(NIH) Pharmacogenomics Research Network (PGRN) and the Clinical Pharmacogenetics
Implementation Consortium (CPIC) includes a strong biological rationale for the gene-drug
association, reproducible evidence linking the genetic variation to drug response, and
noninferiority compared with current prescribing practice (35). The validity of this evidence
threshold is supported by the pharmacogenetic association between TPMT and thiopurine
toxicity, which never underwent an RCT, yet is likely the most validated and commonly
utilized germline pharmacogenetic test in practice.
Another opportunity to generate sufficient evidence to warrant clinical implementation lies
in the drug development process. For example, if preclinical models demonstrate that a drug
is metabolized via a CYP450 enzyme or is a transporter substrate with known or suspected
pharmacogenetic implications (e.g., CYP2D6 or ABCB1) then phase I, II, and III clinical
trials should incorporate correlative studies to examine if the drug disposition is altered
based on CYP450/transporter genotype or altered expression. This approach would allow
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for information to be available from the outset of the drug development process and would
improve the efficiency of the current model, which has required a multitude of retrospective
and prospective studies on drugs that have existed for decades, as correlative
pharmacogenetic studies were traditionally never performed during the initial drug
development process. The capabilities now exist to easily obtain DNA upfront and perform
these studies much earlier. Additionally, it could enhance patient selection, contribute to
dose optimization and therapy selection, and reduce overall healthcare costs from the
beginning. For example, a UGT1A1 genotype-guided phase I study demonstrated that
metastatic colorectal cancer patients lacking the ‘high-toxicity’ genotype (UGT1A1*28/*28)
were able to tolerate significantly higher doses compared to the standard 180 mg/m2
administered in FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) (*1/*1 and *1/*28
patients tolerated up to 370 mg/m2 and 310 mg/m2, respectively) (36). If this genetic
association had been discovered from the outset, clinical studies could have been focused on
tailoring the dose by genotype and testing the hypothesis of improved survival benefit with a
genotype-driven dosing. Furthermore, using genotype to optimize the therapeutic dose may
provide precedence for medications already on the market that have similar pharmacology
and metabolism properties.
The debate of the level of evidence required for clinical utility is further complicated by the
advent of NGS. Because genetic information with known and validated clinical benefits will
be collected and at no additional cost and available with minimal increased effort, it can be
argued that the threshold required to warrant single-gene tests greatly differs from the
threshold to consider when NGS information is readily available. As mentioned previously,
NGS will generate germline information along with somatic. Arguably, it is unethical to
ignore this information given that phenotypes exist that predict life-threatening toxicities
and/or drug efficacy. Indeed, this is the premise of the CPIC guidelines: given that
genotyping information is already available, how should it be utilized by the clinician? (35).
Considering the lower level of evidence that would support clinical utility in this setting, the
true lack of clinical decision support (CDS) and professional organization practice
guidelines is realized.
The challenge of data interpretation in facilitating translation of pharmacogenetics into
clinical practice
The dissemination of pharmacogenetics into clinical practice is largely influenced by the
availability of approved and validated pharmacogenetic tests, clinicians’ ability to use and
understand the tests, and evidence-based recommendations to change therapeutic
management over the current standards. Currently, a paucity of data exists on standardized
pharmacogenetic guidelines by professional organizations, contributing to the slow clinical
uptake of pharmacogenetics. A large survey of 10,303 physicians demonstrated that the vast
majority (97.6%) acknowledged that genetic variations may influence drug response, but
only 10.3% felt adequately informed about pharmacogenetic testing and interpretation (37).
Interestingly, investigators also determined that early adopters of pharmacogenetic testing
are more likely to be practicing in oncology. Thus, despite the large number of FDA-
approved pharmacogenetic tests and drug label indications, readily available consensus
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guidelines and the lack of physician confidence present barriers to widespread
pharmacogenetics implementation into clinical practice.
There are two aspects of data interpretation that affect the translation of pharmacogenetics
into clinical practice: (1) interpretation of published research results and (2) clinician
interpretation of reported genetic results. Firstly, the lack of standardization in conducting
pharmacogenetic studies contributes to inconsistencies in results, which makes interpretation
challenging or even impossible, and contributes to lack of replication in many instances.
Inconsistences between studies include inaccurate or incomplete genotyping (i.e., failure to
include all known functional variants or genotyping of tumor tissue rather than germline
DNA), presence of concomitant medications that may affect drug disposition and/or
response, thus altering observed ‘phenotype’, and the common lack of control groups, which
complicates the differentiation between predictive (associated with response to treatment)
and prognostic (associated with disease outcome in the absence of treatment, i.e., disease
severity) genotypes (38). The discordance between positive associations reported due to
these inconsistences contributes to the complexity of data interpretation by researchers,
professional organizations, consortia, and clinicians alike.
Once a pharmacogenetic association has proven validity and clinical utility and is ready for
clinical implementation, physicians must be willing and able to incorporate it into their
practice. Despite their interest, unfortunately, many physicians lack the confidence and
knowledge required to accurately interpret and implement pharmacogenetics. CDS tools,
which provide physician guidance (most commonly through electronic medical records) on
clinical decisions when pertinent pharmacogenetic information is available, have proven to
successfully enable translation of pharmacogenetics into clinical practice (39). However, in
order to develop accurate recommendations to incorporate into CDS, clear and precise
algorithms based on scientifically robust results must be available to the program
developers; the creation of such algorithms has been facilitated by professional
organizations and consortia discussed below.
An overview of pharmacogenetic recommendations by consortia, professional
organizations, and regulatory bodies
The creation of professional organizations and consortia devoted to pharmacogenetic-
based clinical guidelines and recommendations has provided guidance for uptake into
clinical settings, mainly at large research-intensive academic hospitals, with most
applications being research focused. Examples of such organizations include CPIC and the
Dutch Pharmacogenetics Working Group (DPWG), both devised to create and share
evidence-based clinical pharmacogenetics guidelines with therapeutic recommendations for
specific gene-drug pairs (35, 40). Table 2 summarizes the germline cancer gene-drug pairs
covered by each set of currently available guidelines, as well as a summary of the specific
recommendations provided. Of note, there also exists a Japanese regulatory agency and
recommendations provided by the Japanese Pharmacogenomics Discussion Group (PDG),
which brings together members of the Pharmaceutical and Medical Device Agency (PMDA)
to exchange and share data with the goal of maintaining consistency in consultations and
promoting appropriate pharmacogenetic clinical trials, but they are not readily available in
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English (41). While these organizations have provided helpful guidelines for the most well
validated genetic associations, shortcomings remain.
Notably, the guidelines for somatic mutations tend to be consistent across the different
regulating bodies. For example, guidelines are in agreement that crizotinib is first-line for
patients with the ALK positive NSCLC. The same can be said for vemurafenib in melanoma
patients harboring the BRAF V600E mutation, trastuzumab in HER2-positive breast cancer
patients, as well as the many other drugs with somatic pharmacogenetic implications. This
consistency in guidelines can be explained by the fact that all are targeted agents, which
only received approval in tumor types expressing the biomarker of interest. In contrast, the
retrospective discovery of germline pharmacogenetic markers has contributed to complexity
in the clinical recommendations.
While consortia, professional organizations and regulatory bodies (i.e., the FDA) are
universally concordant in their recommendations for drugs associated with somatic
mutations, extensive discordance exists between the recommendations based on germline
pharmacogenetics (Table 2). Firstly, the gene-drug pairs covered within each set of
guidelines varies. For example, while DPWG, EGAPP, FDA, and National Comprehensive
Cancer Network (NCCN) guidelines exist for UGT1A1-irinotecan gene-drug pair (28,
42-45), the ASCO, CPIC, and the European Medicines Agency (EMA) do not currently
provide guidelines for this specific gene-drug pair. Secondly, the extent and specifics of the
therapeutic recommendations provided in the guidelines are also discordant. While the
DPWG provides broad dose adjustment guidelines for capecitabine based on DPD deficient
phenotype (42), EMA and FDA simply contraindicate the drug in the instance of DPD
deficiency (28, 46), and ASCO states that there is insufficient evidence to recommend
testing or monitoring (47). In the case of NGS, when DPYD genotype will be available, the
question of how to adjust therapy accordingly arises. Likewise, although the FDA and the
majority of the professional organizations and consortia address TPMT testing with
thiopurine administration, the specifics of the recommendations vary. Of note, while the
CPIC and DPWG recommend dose decreases (30-70% and 50%, respectively) to avoid the
risk of severe myelosuppression in patients of the intermediate metabolizer phenotype (42,
48), the FDA label states that these patients usually tolerate normal doses (45). Although
both sets of recommendations may be correct depending on the regimen and its
recommended starting dose (i.e., when the protocol starting dosage of mercaptopurine (MP)
is 75 mg/m2 per day, then dose reductions in heterozygotes is likely necessary, but when the
protocol starting dose of MP is 50 mg/m2, patients are much more likely to tolerate normal
doses), these discrepancies likely prove confusing to unaware clinicians who are trying to
optimally dose TPMT intermediate metabolizers. Thirdly, aside from the discordance among
recommendations, an additional shortcoming is the language included in some of the
recommendations. For example, the FDA and EMA state that capecitabine is contraindicated
in DPD deficient patients, but does not implicitly state the diagnostic criteria for DPD
deficiency (i.e., enzyme expression below a certain level or harboring one or two null
alleles?) (28, 46). The vague nature of this recommendation imposes challenges for
clinicians attempting to apply pharmacogenetics into clinical practice. Similarly, although
EGAPP, EMA, FDA, and NCCN do not specifically recommend UGT1A1 testing in all
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patients receiving irinotecan, they do provide general dosing recommendations for UGT1A1
*28/*28 patients (44-46, 49). In the advent of NGS, this information will be available and
should be acted upon accordingly. The FDA’s recommendation of reducing the dose of
irinotecan by “one level” in UGT1A1 *28/*28 patients receiving irinotecan is subject to
interpretation and, without more detailed recommendations, may result in under- or over-
dosing of these patients (28). Importantly, the only cancer drugs with specific germline
genotype- and phenotype-guided dosing guidelines are thiopurines (provided in the CPIC
and DPWG guidelines), and irinotecan (provided in the DPWG guidelines).
The disparity noted between these guidelines can partially be explained by variations in their
review processes. Interestingly, EGAPP went through several iterations of their review
process methods before even identifying which topics they would focus on for in-depth
reviews and recommendations (31). Another explanation for discordance lies in the
evaluation criteria. While clinical validity of biomarkers is easily evaluable and available,
analytic validity (i.e., how accurately and reliably the test measures the genotype of interest)
and clinical utility are rarely directly available (31). For example, while HER2 status has
been clinically validated (consistently associated with response to trastuzumab), the analytic
validity is variable depending on which assay is used (i.e., fluorescence in situ hybridization,
FISH, or immunohistochemistry, IHC), and clinical utility relies on an assessment of harms
versus benefits, which varies by genotype (50). The lack of objective, standardized measures
of these variables, especially clinical utility, results in the need for some subjectivity when
defining clinical significance, and therefore providing recommendations. A universal
evidence-based approach to evaluating pharmacogenetic literature and developing
recommendations and guidelines would facilitate simplified translation of pharmacogenetics
into clinical practice (50). Importantly, these methods should be established in the context of
NGS to align with the paradigm shift in practice (31).
While the guidelines produced by these professional organizations and consortia are a
step in the right direction, with the universal goal of facilitating implementation of
pharmacogenetics into clinical practice, the discrepancies between the guidelines complicate
translation for clinicians. Additionally, the language used in the recommendations may be
difficult for physicians without an adequate genetics background to understand. For
example, while detailed dosing recommendations provide a thorough summary of the
literature, the complexity introduced with specific phenotyping criteria has the potential to
overwhelm and subsequently deter clinicians without extensive training from adding
pharmacogenetic tests to their regular practice. Concordant, succinct guidelines, with
detailed but clear recommendations would greatly simplify the transition to
pharmacogenetic-guided clinical practice. Furthermore, recommendations on diagnostic
assays or methods of detection would provide clinicians with knowledge on how to obtain
standardized genetic results for interpretation.
Insurance coverage: More than simply cost effectiveness analyses
In the United States, clinical adoption of pharmacogenetics is heavily influenced by the
presence of regulatory recommendations and third-party payment (51). Overall,
reimbursement for pharmacogenetic testing has been inconsistent, and the uncertainty
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regarding payment represents a major barrier to utilization in clinical practice (52). Another
key issue in reimbursement is determining when pharmacogenetic testing is no longer
investigative, but has become clinically validated, for a specific indication (52). As
previously discussed, regulatory agencies require a high threshold of evidence for clinical
recommendations, as do third-party payers who impose the additional requirement of a
reasonable cost, which may explain the high variable payer response in the marketplace
(51). Particularly, an especially high threshold exists for the more expensive genetic-driven
prescriptions for patients whom conventional therapies are predicted to be ineffective or too
toxic. Furthermore, because the current procedural terminology (CPT) codes for germline
pharmacogenetics are limited to single-gene tests and do not include multi-gene, exome or
genome sequencing panels, the tests may be seemingly less important to third-party payers
and, therefore, even more difficult to get covered (53).
Few studies have evaluated the cost effectiveness of cancer pharmacogenetics in practice. Of
note, a cost implications analysis of reactive versus prospective DPYD genotyping in 134
colorectal cancer patients receiving fluorouracil-based therapy revealed the potential for a
total cost saving of €131,165 (~$173,000) through avoiding 5 hospitalizations by
preemptively genotyping the patients (54). Similarly, a cost effectiveness analysis of
screening for KRAS and BRAF mutations in colorectal cancer patients to direct treatment
with cetuximab compared to the base strategy (no anti-EGFR therapy) reported an
incremental cost effectiveness ratio of approximately $650,000 per additional year of life;
the addition of KRAS testing saves approximately $7500 per patient (55). A critical and
systematic review of the cost effectiveness of pharmacogenetics revealed that one of the
most common biomarkers evaluated was TPMT; these studies were focused on a number of
indications for thiopurines, including cancer, inflammatory bowel disease, Crohn's disease,
and rheumatoid arthritis (56). Nonetheless, the review indicated that TPMT genotyping
demonstrated clinical validity and likely demonstrated clinical utility. All six of the studies
included in the analyses reported genotype-guided dosing of thiopurines to be cost effective
when compared to standard dosing. Likewise, UGT1A1*28 genotyping for irinotecan
therapy was also determined to be clinically valid; however, the clinical utility of the test
was classified as unclear (note: only two studies utilizing UGT1A1 genotyping were
included) (56). Both of the cost effectiveness studies assessing preemptive UGT1A1
genotyping demonstrated potential cost effectiveness for the test. Factors that influenced
cost effectiveness analyses included race and whether or not efficacy decreases with reduced
doses in heterozygotes. Specifically, UGT1A1*28 genotyping was shown to be cost saving
for Africans and Caucasians but not Asians, likely due to the low genotype frequency
(observed MAF in Asians: 0.02) (56); the therapeutic efficacy, defined as survival benefit,
of irinotecan in UGT1A1 *28/*28 patients after dose reduction had to be ≥98.4% of full-
dose efficacy for genotype-guided dosing to remain cost-saving (56). This example also
illustrates the compounded difficulty of proving cost effectiveness with low frequency
pharmacogenetic variants due to the high number needed to screen. However, when the
information is readily available due to NGS, the burden of proof is significantly lowered.
Perhaps more relevant in the time of NGS is a recent cost effectiveness analysis of a 21-gene
assay for guiding adjuvant chemotherapy decisions in breast cancer (Oncotype DX,
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Genomic Health, Redwood City, CA), which demonstrated cost effectiveness for
intermediate- and high-risk patients (57). Because this test interrogates more than one gene
at a lower pricing threshold, these results may provide better predictions of the cost-
effectiveness of NGS or other multiple marker tests. That is, compared to a single marker
test which costs around $400-$500, whole genome sequencing can be completed for around
$3000 and will essentially include most, if not all, germline genetic results ever needed for
medication therapy management. In fact, approximately 90% of all bases within the human
exome, regardless of allele frequency, can be captured using current sequencing
technologies (58). The large number of clinically relevant pharmacogenetic genes
interrogated through relatively low-cost NGS further decreases the cost-effectiveness
burden, increasing the willingness to pay for a comprehensive genetic test (59). Of note,
when NGS is not yet performed under Clinical Laboratory Improvement Amendments
(CLIA) conditions (60), additional costs currently associated with NGS include the
requirement for sequencing of biomarkers (or other molecular assays) used for clinical
decision-making to be performed under CLIA. As NGS increasingly becomes more
commonplace, limitations associated with availability of CLIA-certified laboratories will
rapidly subside, and FDA-approved next generation sequencers are likely to be available in
the near future.
As with the level of evidence for clinical implementation debate, a similar challenge lies in
clearly demonstrating cost effectiveness of implementation through comparative
effectiveness trials (61). From a reimbursement perspective, in order to truly evaluate cost
savings, head-to-head studies with and without pharmacogenetic-guided therapy must be
conducted (51). Aside from the low percentage of funding available for this type of research,
this prospective design may not be necessary. For example, retrospective review of data
collected on drugs, pharmacogenetic test usage, and inferred costs from health insurance and
payers’ databases may provide an adequate source of cost information for evaluation. It
must also be taken into consideration that, while the initial drug cost may be higher,
especially in the cancer setting, the money saved by prescribing the optimal therapy from the
beginning (i.e., decreased doctors’ visits and toxicities, improved outcomes) must not be
disregarded.
Pharmacogenetic tests are most likely to be cost effective for medications with serious risks
(i.e., high genotype relative risk or high rates) of toxicity or inefficacy and that are more
expensive, such as chemotherapy agents. Once the price of NGS drops to well less than
$1000 in the near future, the cost-effectiveness debate will likely shift from a focus on
clinical outcomes to a focus on the cost associated with setting up the infrastructure required
to analyze, store the resulting data, and reporting the results of the tests.
As the cost of testing decreases and effectiveness becomes well documented, reimbursement
will be more widely adopted. While it may not be cost effective now to genotype single
variants, as technologies continue to improve and the price for pharmacogenetic tests
continue to drop, the cost effectiveness burden will also continue to decrease rapidly.
Furthermore, as NGS becomes increasingly more common, the potential for derived clinical
benefit from genotyping also multiplies.
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While most clinical and industry efforts are focused on exploring somatic alterations as a
means to target driver mutations, this is not the only key to successfully optimize therapy.
Germline variation can be used to predict and reduce drug toxicity, enhance clinical
efficacy, and inform the potential biology of the tumor. Similarly, researchers and clinicians
must take advantage of the information gained from the numerous sequencing efforts
underway (30). Not only do these projects promote research and discovery, but the
information generated should not be ignored clinically. With NGS technologies, validated
pharmacogenetic gene-drug pairs should be interrogated and acted upon as indicated.
Concordant detailed guidelines would greatly enhance translation into clinical practice.
In order for a genetic test to be adopted into clinical practice, it must provide reliable,
actionable, and predictive information that the clinician would not have otherwise known.
Before clinical implementation of a pharmacogenetic gene-drug pair, robust clinical
evidence is necessary; however, reliance on prospective RCTs as the only way to justify
implementation is unrealistic, and the delay associated with construction, conduction, and
interpretation of results could potentially deprive patients of life-saving or life-extending
therapies. Rather, the DNA samples provided from patients entered into cancer clinical trials
and the drug development process should be exploited to retrospectively discover and
validate pharmacogenetic associations. Previously the discussion had been focused on the
future of pharmacogenetics, when all patients will have pre-emptive genotyping performed
in anticipation of their future medical needs. However, we need to take advantage of what is
happening now – NGS is increasingly common, particularly in the realm of cancer.
Utilization of these sequencing efforts to facilitate pharmacogenetics implementation will
provide the basis for demonstration of uptake and feasibility of mass pre-emptive
implementation.
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Figure 1. Example of the impact of germline pharmacgenetics on drug metabolism and toxicity
Depicted is the pharmacokinetic and pharmacodynamic pathway of irinotecan. Graphs
represent the effect of genotypic variation of key pharmacogenetic genes on the
concentration of SN-38, the active metabolite that is also responsible for toxicities.
Variations in UGT1A1, UGT1A6, UGT1A7, UGT1A9, CYP3A4 and CYP3A5 have been
shown to (directly or indirectly) decrease enzymatic activity, resulting in decreased
glucuronidation (inactivation) and, ultimately, an increase in SN-38 concentration. As
illustrated in the graphs, UGT and CYP activity decreases in an additive manner in variant
carriers (Please note that genetic associations between CYPs and irinotecan are not as
strongly established as those with UGT). Along with this decrease in enzymatic activity,
comes an increase in SN-38 concentration. The line on the graph represents the SN-38
concentration threshold for grade 3/4 (severe) toxicity. As depicted, variant carriers have
SN-38 concentrations that more commonly cross the toxicity threshold. Likewise, variations
in ABCB1, ABCC2, ABCG2, and SCLO1B1 may decrease transporter activity, also resulting
prolonged exposure to SN-38 and increased side effects (Please note that genetic
associations between ABC genes and irinotecan/SN-38 are not as strongly established as
those with UGT)
Abbreviations – WT: wildtype; V: variant
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Figure 2. Example of how next-generation sequencing can be utilized to inform therapeutic
decision-making
In this example, next-generation sequencing (NGS) is performed using both the tumor
(somatic) and inherited (germline) DNA samples. NGS reveals a germline MLH1 variant,
which suggests possible Lynch syndrome (see Table 1). The BRAF wildtype tumor provides
further evidence for this diagnosis, as BRAF mutations are extremely uncommon with Lynch
syndrome. Due to Lynch syndrome, the example patient develops colorectal cancer (CRC).
NGS of a colorectal tumor reveals the patient is KRAS wildtype, thus, is predicted to respond
to an epidermal growth factor receptor (EGFR) inhibitor, such as cetuximab. The clinician
decides to start the patient on the first-line treatment option of FOLFIRI [folinic acid
(leucovorin), fluorouracil (5-FU), and irinotecan] + cetuximab. Germline NGS information
can be used to further optimize dose selection and management. Specifically, the patient is
determined to carry two reduced-activity UGT1A1 alleles (*28/*28), putting him at an
increased risk for severe irinotecan toxicity (neutropenia); a dose reduction is recommended.
Additionally, the patient carries one inactive DPYD allele, which may warrant a 5-FU dose
decrease. If the patient has encounters indications for other medications with validated
pharmacogenetic associations (e.g., warfarin or amitriptyline in this case), that information
will also be provided through NGS and should be readily available to inform drug decisions.
*Note: Germline variants may or may not also be present on the somatic genome.
Abbreviations – AE: adverse event; CRC: colorectal cancer; INR: international normalized
ratio; TCAs: tricyclic antidepressants; TDM: therapeutic drug monitoring; VTE: venous
thromboembolism
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